Sign in

    Daniel Krizay

    Vice President of Biotech Equity Research at Guggenheim Partners, LLC

    Daniel Krizay is a Vice President of Biotech Equity Research at Guggenheim Partners, specializing in the biotechnology sector and providing equity research coverage for leading biotech firms such as Insmed. He brings over a decade of experience in biopharmaceutical equity analysis, having joined Guggenheim Partners in a senior analytical capacity and participating in high-profile industry events. According to FINRA, Krizay is registered with Guggenheim Securities, LLC, and holds the requisite securities licenses for his role, reflecting his strong compliance standing and depth of expertise. His career is marked by a consistent focus on biotech equities, with a performance track record connected to actionable company insights and investor engagement.

    Daniel Krizay's questions to ANI PHARMACEUTICALS (ANIP) leadership

    Daniel Krizay's questions to ANI PHARMACEUTICALS (ANIP) leadership • Q2 2025

    Question

    Daniel Krizay, on for Vamil Divan, asked if specific medical specialties were adopting the Cortrophin prefilled syringe more rapidly than others. He also questioned whether the positive results from the ILUVIEN New Day trial had any impact on the updated 2025 guidance, potentially offsetting the negative market access challenges.

    Answer

    President, Director & CEO Nikhil Lalwani explained that the adoption of the prefilled syringe has been broad across all indications due to its ease of use, rather than being concentrated in any particular specialty. Regarding ILUVIEN, he acknowledged the positive feedback on the New Day study data but clarified that no specific upside from these results was factored into the revised guidance for the second half of the year.

    Ask Fintool Equity Research AI